Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.

Abstract: Nucleic acid agents for reducing or removing infestations of the Varroa destructor mite are described. Compositions comprising the nucleic acid agents and methods for controlling mite infestations using the nucleic acid agents and compositions are also disclosed.

Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.

Abstract: A liquid crystal cell includes substrates defining a gap and electrodes having one of (i) an in-plane geometry generating an electric field parallel with the substrates and (ii) a top-down geometry generating an electric field across the gap between the two spaced apart substrates. A liquid crystal material disposed in the gap between the substrates comprises a chiral nematic material formed by a mixture of: 1-(4-cyanobiphenyl-4?-yl)-6-(4-cyanobiphenyl-4?-yloxy)hexane (CB6OCB) or ?,?-bis(4,4-cyanobiphenyl)nonane (CB9CB) dimeric liquid crystal material; at least one additional dimeric liquid crystal material; and a chiral dopant.

Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.

Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprise a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?x+y where 0<x<1.3 and 0<y<1:3.

Abstract: The present invention relates to a converter for transferring power between a first DC system of DC voltage V1 and a second DC system of DC voltage V2, the converter comprising: —a first AC/DC converter for transforming DC voltage V1 into a first single phase AC voltage V1ac, of frequency ?, root mean square line-neutral magnitude V1acm and angle ?1; a second AC/DC converter for transforming DC voltage V2 into a second single phase AC voltage V2ac, of frequency ?, root mean square line-neutral magnitude V2acm and angle ?2; and two inductors L1, L2 and a capacitor C, wherein the first terminals of the inductors and capacitor are connected together, the second terminal of inductor L1 and the second terminal of the capacitor C are connected to the first AC voltage V1ac, and the second terminal of inductor L2 and the second terminal of the capacitor C are connected to the second AC voltage V2ac; wherein the value of the capacitor C, inductor L1 and inductor L2 are selected to enable required power transfer and to

Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.

Abstract: The present invention provides compositions for inhibiting the activity of an insect pest against a subject (or repelling an insect pest from an environment or preventing attraction to an environment) which compositions comprise geranylacetone as an active ingredient plus a carrier plus a further active ingredient selected from the list consisting of: 6-Methyl-hepten-2-one, octanal, plus optional other chemicals. Also provided are related materials and methods of use.

Abstract: The present invention provides a process for the preparation of a silicate and carbonate co-substituted calcium phosphate material. The process comprises the steps of: forming a silicon and optionally carbon-containing calcium phosphate precipitate by an aqueous precipitation method involving preparing an aqueous solution comprising phosphate ions, silicate ions, calcium ions and optionally carbonate ions, wherein the ratio of Ca/P and of Ca/(P+Si) in the solution is maintained above approximately 1.67; and heating the precipitate in an atmosphere comprising carbon and oxygen to form a silicate and carbonate co-substituted calcium phosphate material. The present invention also provides a synthetic carbonate and silicate co-substituted hydroxyapatite material, as well as a biomedical material.

Abstract: The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.

Abstract: A process for the synthesis of a bioceramic composition comprising calcium phosphosilicate (CPS, Ca10(PO4)4(SiO4)2), the process comprising: providing calcium or a calcium-containing compound, a phosphorus-containing compound and a silicon-containing compound; and forming a precipitate by reacting the compounds in an aqueous phase at an alkali pH.

Abstract: This invention relates to the in vitro production of cyclic peptides using cyanobacterial enzymes, such as patellamide biosynthesis enzymes. Linear peptide substrates are cyclized using an isolated cyanbacterial macrocyclase, such as PatG from Prochloron spp. Before cyclisation, residues in the linear peptide substrates may be heterocyclised using isolated cyanbacterial heterocyclases, such as PatD or TruD heterocyclase. Methods of the invention may be useful, for example, for the production of cyclic peptidyl molecules, including cyclotides, such as katalas, and cyanobactins, such as patellamides and telomestatins, for example for use in the development of therapeutics.

Abstract: The present invention pertains to a protein having the characteristics of a serine protease having an amino acid sequence according to SEQ ID NO 2 for use as a medicament. The invention also pertains to this protein for use in a vaccine to protect an animal against an infection with a micro organism that secretes said protein, and to the corresponding antibodies directed against the protein.

Abstract: A concrete mixture for forming a breathable concrete. The mixture comprises aggregate particles and a paste comprising water, cement or cement substitute, and plasticizer. The plasticizer controls the viscosity of the paste such that the paste forms a substantially uniform layer coating the particles, with the coated particles in contact, while allowing spaces to be retained there between. These spaces interconnect forming channels through the concrete, allowing air to permeate there through such that the concrete exhibits good dynamic insulation properties, whist retaining structural strength.

Abstract: The invention relates to porous granular calcium phosphate osteoinductive materials, particularly materials useful in body tissue repair, principally bone repair and bone replacement, and also to the use of such materials and to a method of making such materials. Exemplary materials comprise discrete porous granules each containing crystals of at least one calcium phosphate, wherein (i) at least 90% of said crystals of the granules have a crystal size in the range 10-100 nm, (ii) at least 90% of the pores in the granules have a pore size in the range 10-500 nm, (iii) the average pore size of the pores having pore size in the range 10-500 nm in the granules is in the range 30-90 nm, (iv) the total volume porosity of the granules is at least 50%, and (v) the surface area of the granules is in the range 10-70 m2/g.

Abstract: Apparatus (1) for use in a method for psychiatric evaluation comprises: memory means (4) for holding a store of pre-selected images; display means (12) for displaying a succession of said images to a patient; eye tracking means (6) for tracking eye movement of a patient; recording means (8) for recording eye movement data corresponding to a patient's eye movement in response to the display of said succession of images; control means (2) for controlling the display means to display the images to the patient, and for controlling the recording means to record said eye movement data and displayed image data; and evaluation means (10) for evaluating said eye movement data and displayed image data for use in identifying a psychiatric profile of the patient.

Abstract: The present invention provides a process for the preparation of a silicate and carbonate co-substituted calcium phosphate material. The process comprises the steps of: forming a silicon and optionally carbon-containing calcium phosphate precipitate by an aqueous precipitation method involving preparing an aqueous solution comprising phosphate ions, silicate ions, calcium ions and optionally carbonate ions, wherein the ratio of Ca/P and of Ca/(P+Si) in the solution is maintained above approximately 1.67; and heating the precipitate in an atmosphere comprising carbon and oxygen to form a silicate and carbonate co-substituted calcium phosphate material. The present invention also provides a synthetic carbonate and silicate co-substituted hydroxyapatite material, as well as a biomedical material.

Abstract: A process for the synthesis of a bioceramic composition comprising calcium phosphosilicate (CPS, Ca10(PO4)4(SiO4)2), the process comprising: providing calcium or a calcium-containing compound, a phosphorus-containing compound and a silicon-containing compound; and forming a precipitate by reacting the compounds in an aqueous phase at an alkali pH.

Abstract: The present invention relates to a converter for transferring power between a first DC system of DC voltage V1 and a second DC system of DC voltage V2, the converter comprising: —a first AC/DC converter for transforming DC voltage V1 into a first single phase AC voltage V1ac, of frequency ?, root mean square line-neutral magnitude V1acm and angle ?1; a second AC/DC converter for transforming DC voltage V2 into a second single phase AC voltage V2ac, of frequency ?, root mean square line-neutral magnitude V2acm and angle ?2; and two inductors L1, L2 and a capacitor C, wherein the first terminals of the inductors and capacitor are connected together, the second terminal of inductor L1 and the second terminal of the capacitor C are connected to the first AC voltage V1ac, and the second terminal of inductor L2 and the second terminal of the capacitor C are connected to the second AC voltage V2ac; wherein the value of the capacitor C, inductor L1 and inductor L2 are selected to enable required power transfer and to